NO863082L - PREPARATION FOR INTRAMUSCULAR INJECTION OF PHARMACEUTICALS, VITAMINS OR VACCINES. - Google Patents

PREPARATION FOR INTRAMUSCULAR INJECTION OF PHARMACEUTICALS, VITAMINS OR VACCINES.

Info

Publication number
NO863082L
NO863082L NO863082A NO863082A NO863082L NO 863082 L NO863082 L NO 863082L NO 863082 A NO863082 A NO 863082A NO 863082 A NO863082 A NO 863082A NO 863082 L NO863082 L NO 863082L
Authority
NO
Norway
Prior art keywords
glucoheptonate
racemic
salt
preparation
preparation according
Prior art date
Application number
NO863082A
Other languages
Norwegian (no)
Other versions
NO863082D0 (en
Inventor
Faruk Hadziselimovic
Original Assignee
Mepha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mepha Ag filed Critical Mepha Ag
Publication of NO863082L publication Critical patent/NO863082L/en
Publication of NO863082D0 publication Critical patent/NO863082D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The addition of pharmaceutically accepted hydrosoluble organic or inorganic calcium salts, particularly calcium glucoheptonate to a drug, vitamin or vaccine to be administered by intramuscular injection enables to obtain a painless injection without adding local anaesthetics.

Description

Foreliggende oppfinnelse vedrører et preparat for intramuskulær injeksjon av medikamenter eller vitaminer eller vaksiner, som inneholder et vannoppløselig kalsiumsalt av en organisk eller uorganisk syre, spesielt Ca-glukoheptanoat i racemisk, D- eller L-form. The present invention relates to a preparation for intramuscular injection of drugs or vitamins or vaccines, which contains a water-soluble calcium salt of an organic or inorganic acid, especially Ca-glucoheptanoate in racemic, D or L form.

Intramuskulære injeksjoner av medikamenter eller vitaminer og vaksiner kan være meget smertefulle. For å redusere eller forhindre den reaksjonen har man hittil som farmasøytiske tilsatsstoffer tilsatt lokal bedøvelsesmidler, som f.eks. lidokainhydroklorid eller mepivakainhydro-klorid, til medikamentet eller vitaminen eller vaksinen. Intramuscular injections of drugs or vitamins and vaccines can be very painful. In order to reduce or prevent that reaction, local anesthetics, such as e.g. lidocaine hydrochloride or mepivacaine hydrochloride, to the drug or vitamin or vaccine.

Nå er det imidlertid f.eks. kjent at lokalbedøvelsesmidler og også mange medikamenter, spesielt penicilliner, kan utløse et anafylaktisk sjokk ved injeksjon. Denne reaksjonen regnes f.eks. i USA som den hyppigst opptrendende dødsårsaken i medisinske preparatpraksiser, og i Frankrike dør 2 av 10.000 tilfeller pr. år. Now, however, it is e.g. known that local anesthetics and also many drugs, especially penicillins, can trigger an anaphylactic shock when injected. This reaction is considered e.g. in the USA as the most frequently trending cause of death in medical preparation practices, and in France 2 out of 10,000 cases die per year.

Formålet med foreliggende oppfinnelse var følgelig å tilveiebringe et tilsatsstoff, som tillater smertefrie injeksjoner av medikamenter, vitaminer og vaksiner, men som ikke oppviser de farlige bivirkningene for kjente midler for lokal smertestillelse. The purpose of the present invention was therefore to provide an additive which allows painless injections of drugs, vitamins and vaccines, but which does not exhibit the dangerous side effects of known agents for local pain relief.

Det er nå overraskende funnet at man ved tilsats av farmasøytisk akseptable, vannoppløselige Ca-salter av organiske eller uorganiske syrer, spesielt Ca-glukoheptonat, til medikamentet, vitaminen eller vaksinen, sterkt kan redusere, henholdsvis total unngå, den smerten som opptrer ved den intramuskulære injeksjonen, unngå de farlige allergireaksjonene knyttet til lokalbedøvelsesmidler og videre forhindre eller sterkt redusere de medikament-betingede allergireaksjonene. It has now surprisingly been found that by adding pharmaceutically acceptable, water-soluble Ca salts of organic or inorganic acids, especially Ca-glucoheptonate, to the drug, vitamin or vaccine, the pain that occurs during the intramuscular the injection, avoid the dangerous allergic reactions associated with local anesthetics and further prevent or greatly reduce the drug-related allergic reactions.

Som eksempler på farmasøytisk akseptable Ca-salter kan nevnes: Ca-saltet av laktobionsyre, levulinsyre eller melkesyre, og spesielt Ca-glukoheptonat eller kalsiumsulfat. Disse kan tilsette enkeltvis eller som blanding til medikamentet, vitaminen eller vaksinen som skal injiseres. Examples of pharmaceutically acceptable Ca salts can be mentioned: the Ca salt of lactobionic acid, levulinic acid or lactic acid, and especially Ca glucoheptonate or calcium sulphate. These can be added individually or as a mixture to the drug, vitamin or vaccine to be injected.

Preparatet ifølge oppfinnelsen fremstilles ved blanding av medikamentet, vitaminen eller vaksinen med det farmasøytisk akseptable Ca-saltet, spesielt Ca-glukoheptonat, på i og for seg kjent måte. Ca-saltet tilsettes herunder normalt i oppløst form, f.eks. til medikamentet. Som opp-løsningsmiddel kan man anvende H2O, destillert eller dobbelt-destillert, fysiologisk NaCl-oppløsning eller 5% glukose-oppløsning. Til dette tilsettes ca. 0,01% til 25%, spesielt ca. 10% Ca-salt og oppløses deri. Det på denne måten oppløste Ca-saltet kan så blandes med medikamentet, vitaminen eller vaksinen, hvorved konsentrasjonen av Ca-saltet i oppløsningsmiddelet og tilsatsmengden til medikamentet, vitaminen eller vaksinen avhenger av typen og mengden av stoffet som skal injiseres, og f.eks. ved penicillin G pr. 300.000 I.E. kan utgjøre 0,5 til 2,5 ml 10% Ca-glukoheptonat - oppløsning. The preparation according to the invention is prepared by mixing the drug, vitamin or vaccine with the pharmaceutically acceptable Ca salt, in particular Ca glucoheptonate, in a manner known per se. The Ca salt is normally added below in dissolved form, e.g. to the medication. H2O, distilled or double-distilled, physiological NaCl solution or 5% glucose solution can be used as a solvent. To this is added approx. 0.01% to 25%, especially approx. 10% Ca salt and dissolve therein. The Ca salt dissolved in this way can then be mixed with the drug, vitamin or vaccine, whereby the concentration of the Ca salt in the solvent and the amount added to the drug, vitamin or vaccine depends on the type and quantity of the substance to be injected, and e.g. with penicillin G per 300,000 I.E. may amount to 0.5 to 2.5 ml of 10% Ca-glucoheptonate - solution.

Det er også mulig å koble Ca-saltet ved kjemisk reaksjon til medikamentet, vitaminet eller vaksinen. It is also possible to connect the Ca salt by chemical reaction to the drug, vitamin or vaccine.

Generelt forsterkes den smertestillende virkningen ved injeksjonen ved forhøyelse av konsentrasjonen og/eller mengden av oppløst Ca-salt. In general, the pain-relieving effect of the injection is enhanced by increasing the concentration and/or amount of dissolved Ca salt.

Intramuskulære injeksjoner av depotantibiotika og vitamin E egner seg spesielt godt for anvendelsen av farmasøytisk akseptable Ca-salter for å oppnå smertefri injeksjon. Intramuscular injections of depot antibiotics and vitamin E lend themselves particularly well to the use of pharmaceutically acceptable Ca salts to achieve painless injection.

Oppfinnelsen skal i det følgende beskrives nærmere ved hjelp av de følgende eksemplene. In the following, the invention will be described in more detail using the following examples.

Eksempel 1Example 1

I en desinfisert, tørr ampulle av benzatin-benzylpenicillin 600.000 LE. injiseres 2 ml av en 10% vandig Ca-glukoheptonatoppløsning og ristes inntil innholdet er suspendert. Suspensjonen injiseres i en forsøksperson intraglutealt, loco classico. Forsøkspersonen føler derved ikke de typiske smertene som vanligvis oppstår ved intramuskulære penicillin-injek sjoner. In a disinfected, dry ampoule of benzathine-benzylpenicillin 600,000 LE. inject 2 ml of a 10% aqueous Ca-glucoheptonate solution and shake until the contents are suspended. The suspension is injected into a subject intragluteally, loco classico. The subject thereby does not feel the typical pain that usually occurs with intramuscular penicillin injections.

Eksempel 2Example 2

1 ml vitamin Bj (= 100 ug tiamin) suspenderes i 3 ml av en 10% vandig Ca-glukoheptonatoppløsning og injiseres i en forsøksperson analogt eksempel 1. Forsøkspersonen føler derved ikke de typiske smertene som vanligvis oppstår ved intramuskulære vitamin-Bj-injeksjoner. 1 ml of vitamin Bj (= 100 ug thiamine) is suspended in 3 ml of a 10% aqueous Ca-glucoheptonate solution and injected into a subject analogously to example 1. The subject thereby does not feel the typical pains that usually occur with intramuscular vitamin Bj injections.

Eksempel 3Example 3

1 ml vitamin Bj (= 100 pg tiamin) suspenderes i 1,51 av en 10% vandig Ca-glukoheptonatoppløsning og injiseres deretter i forsøkspersonen analogt eksempel 1. Forsøkspersonen føler derved ikke de typiske smertene som vanligvis oppstår ved intramuskulære vitamin Bj-injeksjoner. 1 ml of vitamin Bj (= 100 pg thiamine) is suspended in 1.51 of a 10% aqueous Ca-glucoheptonate solution and then injected into the subject analogously to example 1. The subject thereby does not feel the typical pains that usually occur with intramuscular vitamin Bj injections.

Eksempel 4Example 4

1 en desinfisert, tørr ampulle av benzylpenicillin-Na 500.000 LE. injiseres 2 ml av en 5% vandig Ca-glukoheptonatoppløsning og ristes inntil innholdet er suspendert. Suspensjonen injiseres i en forsøksperson intraglutealt, loco classico. Forsøkspersonen føler derved ikke de typiske smertene som vanligvis oppstår ved intramuskulære penicillininjeksjoner. 1 a disinfected, dry ampoule of benzylpenicillin-Na 500,000 LE. inject 2 ml of a 5% aqueous Ca-glucoheptonate solution and shake until the contents are suspended. The suspension is injected into a subject intragluteally, loco classico. The subject thereby does not feel the typical pain that usually occurs with intramuscular penicillin injections.

Eksempel 5Example 5

"Mumpsvax" (kusma-levendevirus-vaksine, MSD) med minst 5.000 TCID5ø/dose suspenderes i 0,5 ml 10% Ca-glukoheptonatoppløsning og injiseres subkutant i en forsøksperson. Forsøkspersonen føler under dette ingen typiske smerter. "Mumpsvax" (mumps live virus vaccine, MSD) with at least 5,000 TCID5ø/dose is suspended in 0.5 ml of 10% Ca-glucoheptonate solution and injected subcutaneously into a subject. During this, the subject does not feel any typical pain.

Eksempel 6Example 6

"M-M-Rrr" (mesling-, kusma- og røde hunder-levendevirus-vaksine, MSD), sammensatt av 1. "Attenuvax" (Mesling-levendevirus-vaksine, MSD), 2. "Mumpsvax" (kusma-levendevirus-vaksine, MSD) og 3. "Meruvax" (røde hunder-levendevirus-vaksine, MSD) og inneholdende minst 1.000 TCID50(vevskultur-infeksjonsdoser) mesling-levendevirus-vaksine, 5.000 TCID50kusma-levendevirus-vaksine og 1.000 TCID50røde hunder-levendevirus-vaksine, suspenderes i 1 ml 10% Ca-glukoheptonatoppløsning og injiseres subkutant i en forsøksperson. Tilførselen er praktisk talt smertefri. "M-M-Rrr" (measles, mumps and rubella live virus vaccine, MSD), composed of 1. "Attenuvax" (Measles live virus vaccine, MSD), 2. "Mumpsvax" (mumps live virus vaccine , MSD) and 3. "Meruvax" (rubella live virus vaccine, MSD) and containing at least 1,000 TCID50 (tissue culture infectious doses) measles live virus vaccine, 5,000 TCID50 mumps live virus vaccine and 1,000 TCID50 rubella live virus vaccine, is suspended in 1 ml of 10% Ca-glucoheptonate solution and injected subcutaneously into a subject. The delivery is practically painless.

Claims (9)

1. Preparat for intramuskulær injeksjon av medikamenter, vitaminer eller vaksiner, karakterisert ved at det inneholder et vannoppløselig kalsiumsalt av en organisk eller uorganisk syre, spesielt Ca-glukoheptonat i racemisk, D- eller L-form.1. Preparation for intramuscular injection of drugs, vitamins or vaccines, characterized in that it contains a water-soluble calcium salt of an organic or inorganic acid, especially Ca-glucoheptonate in racemic, D or L form. 2. Anvendelse av vannoppløselige Ca-salter av en organisk eller uorganisk syre, spesielt Ca-glukoheptonatet i racemisk, D- eller L-form, til fremstilling av et preparat som kan injiseres intramuskulært uten smerte.2. Use of water-soluble Ca salts of an organic or inorganic acid, in particular Ca glucoheptonate in racemic, D or L form, for the preparation of a preparation which can be injected intramuscularly without pain. 3. Preparat ifølge krav 1 eller 2, karakterisert ved at det som Ca-salt tilsettes kalsiumsulfat, Ca-saltet av laktobionsyre, levulinsyre eller melkesyre, eller spesielt Ca-glukoheptonat i racemisk, D- eller L-form, enkeltvis eller som blanding, til medikamentet, vitaminet eller vaksinen.3. Preparation according to claim 1 or 2, characterized in that calcium sulfate, the Ca salt of lactobionic acid, levulinic acid or lactic acid, or especially Ca glucoheptonate in racemic is added as Ca salt, D or L form, individually or as a mixture, for the drug, vitamin or vaccine. 4. Preparat ifølge et av kravene 1 til 3, karakterisert ved at Ca-saltet tilsettes oppløst i H2 O, destillert eller dobbelt-destillert, fysiologisk NaCl-oppløsning eller 5% glukose-oppløsning til medikamentet.4. Preparation according to one of claims 1 to 3, characterized by that the Ca salt is added dissolved in H2 O, distilled or double-distilled, physiological NaCl solution or 5% glucose solution to the drug. 5. Preparat ifølge et av kravene 1 til 4, karakterisert ved at Ca-saltet anvendes i en konsentrasjon i - oppløsningsmiddelet på 0,01 til 25%, spesielt på 10%.5. Preparation according to one of claims 1 to 4, characterized by that the Ca salt is used in a concentration in the solvent of 0.01 to 25%, especially of 10%. 6. Preparat ifølge krav 5, karakterisert ved at det anvendes en vandig Ca-glukoheptonatoppløsning i racemisk, D- eller L-form.6. Preparation according to claim 5, characterized in that an aqueous Ca-glucoheptonate solution is used in racemic, D or L form. 7. Preparat ifølge et av kravene 1 til 6, karakterisert ved at det pr. 300.000 LE. penicillin tilsettes 0,5 til 2,5 ml, spesielt 1 til 1,5 ml 10% Ca-saltoppløsning.7. Preparation according to one of claims 1 to 6, characterized by that per 300,000 LE. penicillin is added to 0.5 to 2.5 ml, especially 1 to 1.5 ml of 10% Ca-saline solution. 8. Preparat ifølge krav 7, karakterisert ved at det tilsettes 1 til 1,5 ml Ca-glukoheptonatoppløsning i racemisk, D- eller L-form.8. Preparation according to claim 7, characterized in that 1 to 1.5 ml of Ca-glucoheptonate solution in racemic, D or L form is added. 1. Preparat for intramuskulær injeksjon av medikamenter, vitaminer eller vaksiner, karakterisert ved at det inneholder et vannoppløselig kalsiumsalt av en organisk eller uorganisk syre, spesielt Ca-glukoheptonat i racemisk, D- eller L-form.1. Preparation for intramuscular injection of drugs, vitamins or vaccines, characterized in that it contains a water-soluble calcium salt of an organic or inorganic acid, especially Ca-glucoheptonate in racemic, D or L form. 2. Anvendelse av vannoppløselige Ca-salter av en organisk eller uorganisk syre, spesielt Ca-glukoheptonatet i racemisk, D- eller L-form, til fremstilling av et preparat som kan injiseres intramuskulært uten smerte.2. Use of water-soluble Ca salts of an organic or inorganic acid, in particular Ca glucoheptonate in racemic, D or L form, for the preparation of a preparation which can be injected intramuscularly without pain. 3. Anvendelse av vannoppløselige Ca-salter av en organisk eller uorganisk syre, spesielt Ca-glukoheptonatet i racemisk, D- eller L-form, for å oppnå smertefri intramuskulær injeksjon av medikamenter, spesielt antibiotika, vaksiner eller vitaminer.3. Application of water-soluble Ca salts of an organic or inorganic acid, in particular the Ca glucoheptonate in racemic, D or L form, to achieve painless intramuscular injection of drugs, in particular antibiotics, vaccines or vitamins. 4. Preparat ifølge et av kravene 1 til 3, karakterisert ved at det som Ca-salt tilsettes kalsiumsulfat, Ca-saltet av laktobionsyre, levulinsyre eller melkesyre, eller spesielt Ca-glukoheptonatet i racemisk, D- eller L-form, enkeltvis eller som blanding, i medikamentet, vitaminet eller vaksinen.4. Preparation according to one of claims 1 to 3, characterized by that as Ca salt, calcium sulphate, the Ca salt of lactobionic acid, levulinic acid or lactic acid, or especially Ca glucoheptonate in racemic, D or L form, individually or as a mixture, is added to the medicine, vitamin or vaccine. 5. Preparat ifølge et av kravene 1 til 4, karakterisert ved at Ca- saltet tilsettes oppløst i H2 O, destillert eller dobbelt-destillert, fysiologisk NaCl-oppløsning eller 5% glukose-oppløsning til medikamentet.5. Preparation according to one of claims 1 to 4, characterized by that the Ca salt is added dissolved in H2 O, distilled or double-distilled, physiological NaCl solution or 5% glucose solution to the drug. 6. Preparat ifølge et av patentkravene 1 til 5, karakterisert ved at Ca-saltet anvendes i en konsentrasjon i oppløsningsmiddel på 0,01 til 25%, spesielt på 10%.6. Preparation according to one of the patent claims 1 to 5, characterized in that the Ca salt is used in a concentration in solvent of 0.01 to 25%, especially of 10%. 7. Preparat ifølge krav 6, karakterisert ved at det anvendes en vandig Ca-glukoheptonatoppløsning i racemisk, D- eller L-form.7. Preparation according to claim 6, characterized in that an aqueous Ca-glucoheptonate solution is used in racemic, D or L form. 8. Preparat ifølge et av kravene 1 til 7, karakterisert ved at det pr. 300.000 LE. penicillin tilsettes 0,5 til 2,5 ml, spesielt 1 til 1,5 ml, 10% Ca-saltoppløsning.8. Preparation according to one of claims 1 to 7, characterized by that per 300,000 LE. penicillin is added 0.5 to 2.5 ml, especially 1 to 1.5 ml, of 10% Ca-saline solution. 9. Preparat ifølge krav 8, karakterisert ved at det tilsettes 1 til 1,5 ml Ca-glukoheptonatoppløsning i racemisk D- eller L-form.9. Preparation according to claim 8, characterized in that 1 to 1.5 ml of Ca-glucoheptonate solution in racemic D or L form is added.
NO1986863082A 1984-12-07 1986-07-30 PREPARATION FOR INTRAMUSCULAR INJECTION OF PHARMACEUTICALS, VITAMINS OR VACCINES. NO863082D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH586084 1984-12-07
PCT/CH1985/000172 WO1986003413A1 (en) 1984-12-07 1985-12-06 Preparations for the intramuscular injection of drugs, vitamins or vaccines

Publications (2)

Publication Number Publication Date
NO863082L true NO863082L (en) 1986-07-30
NO863082D0 NO863082D0 (en) 1986-07-30

Family

ID=4300514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO1986863082A NO863082D0 (en) 1984-12-07 1986-07-30 PREPARATION FOR INTRAMUSCULAR INJECTION OF PHARMACEUTICALS, VITAMINS OR VACCINES.

Country Status (9)

Country Link
EP (1) EP0204737B1 (en)
KR (1) KR870700024A (en)
AT (1) ATE74523T1 (en)
AU (1) AU5198686A (en)
DE (1) DE3585835D1 (en)
DK (1) DK365786A (en)
FI (1) FI863192L (en)
NO (1) NO863082D0 (en)
WO (1) WO1986003413A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267962B1 (en) 1990-12-21 2001-07-31 C-P Technology Limited Partnership Compositions and methods of treatment using peat derivatives
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
NO20014746D0 (en) 2001-09-28 2001-09-28 Clas M Kjoelberg Pain reliever
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
WO2006012700A1 (en) * 2004-08-04 2006-02-09 Team Health Pty Ltd Method of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1023821A (en) * 1950-04-21 1953-03-24 Stable solution of calcium gluconate and process for its preparation
DE1007022B (en) * 1953-06-02 1957-04-25 Sandoz Ag Process for improving the shelf life and solubility of antihistamine preparations
DE1062389B (en) * 1958-02-11 1959-07-30 Wander Ag Dr A Process for the preparation of sterile vitamin D solutions containing calcium salts
US4081527A (en) * 1976-12-07 1978-03-28 Pfizer Inc. Chlortetracycline compositions

Also Published As

Publication number Publication date
DK365786D0 (en) 1986-07-31
AU5198686A (en) 1986-07-01
DK365786A (en) 1986-07-31
EP0204737A1 (en) 1986-12-17
NO863082D0 (en) 1986-07-30
ATE74523T1 (en) 1992-04-15
FI863192A7 (en) 1986-08-05
WO1986003413A1 (en) 1986-06-19
KR870700024A (en) 1987-02-28
FI863192A0 (en) 1986-08-05
EP0204737B1 (en) 1992-04-08
DE3585835D1 (en) 1992-05-14
FI863192L (en) 1986-08-05

Similar Documents

Publication Publication Date Title
US5209724A (en) Composite anesthetic article and method of use
JPH02101022A (en) Medicine composition for treating diabetes
JPH0222220A (en) Stable drug preparation and production thereof
US4816439A (en) The use of human growth hormone for the treatment of intoxicated individuals
Ozcan et al. Update on the use of lipid emulsions in local anesthetic systemic toxicity: a focus on differential efficacy and lipid emulsion as part of advanced cardiac life support
ES2215856T3 (en) SOLUTION OF MONOSODIC SALT TETRAHYDRATE OF N- (O- (P-PIVALOYLOXIBENCENO-SULFONYLAMINE) BENZOIL) GLYCINE AND MEDICINAL PRODUCT CONTAINING THIS SOLUTION.
EP0204737B1 (en) Preparations for the intramuscular injection of drugs, vitamins or vaccines
US3548052A (en) Heparin compositions and methods of using same
WO1981001653A1 (en) Sedative drug
CA2496121A1 (en) Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
Cook Chemical immobilization of black bears in Great Smoky Mountains National Park
DE3044753C2 (en)
JP2020519593A (en) Drug-containing preparation with enhanced solubility
JPH05170664A (en) Stable peptide drug composition
US4259322A (en) Method of treatment of tuberculosis
RU2680804C1 (en) Stable treatment for joints diseases
RU2045961C1 (en) Method of experimental coronarography
HU207455B (en) Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent
RU2290922C1 (en) Agent for treatment of joint diseases
Blotner et al. The effect of insulin, pituitrin and adrenalin on the blood-sugar level
RU2066181C1 (en) Antitumor agent
RU2157698C1 (en) Method of preparing preparation "pensulin cc" of insulin suspension for cartridge
JPS63303931A (en) Drug preparation for transnasal administration having growth hormone releasing activity
JPS6237017B2 (en)
AU2018437600B2 (en) Novel pentosan polysulfate sodium preparation